UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 175

Sortiert nach

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5008-5008

2019

Volltextzugriff (PDF)

Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): A post-hoc analysis of the SPARTAN phase III trial

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.157-157

2023

Volltextzugriff (PDF)

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

The New England journal of medicine, 2013-04, Vol.368 (14), p.1314-1325

2013

Volltextzugriff (PDF)

Evaluating changes in “good safety monitoring” for cancer clinical trial participants during the COVID-19 pandemic

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.217-217

2021

Volltextzugriff (PDF)

Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1590-1590

2020

Volltextzugriff (PDF)

Disparities in germline testing by race/ethnicity and preferred language in patients with prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.112-112

2023

Volltextzugriff (PDF)

Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.38-38

2021

Volltextzugriff (PDF)

Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.66-66

2021

Volltextzugriff (PDF)

Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.37-37

2021

Volltextzugriff (PDF)

Ethnic disparities among men with prostate cancer undergoing germline testing

Urologic oncology, 2020-03, Vol.38 (3), p.80.e1-80.e7

2020

Volltextzugriff (PDF)

HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.370-370

2022

Volltextzugriff (PDF)

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

European journal of cancer (1990), 2023-05, Vol.185, p.178-215

2023

Volltextzugriff (PDF)

Patterns in cancer management changes for patients with COVID-19 in northern California

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1535-1535

2021

Volltextzugriff (PDF)

Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.442-442

2021

Volltextzugriff (PDF)

Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3001-3001

2022

Volltextzugriff (PDF)

Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5032-5032

2018

Volltextzugriff (PDF)

The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5045-5045

2021

Volltextzugriff (PDF)

Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.73-73

2022

Volltextzugriff (PDF)

Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.267-267

2018

Volltextzugriff (PDF)

Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5032-5032

2023

Volltextzugriff (PDF)

Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17010-e17010

2023

Volltextzugriff (PDF)

AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5027-5027

2023

Volltextzugriff (PDF)

Digital histopathology-based multimodal artificial intelligence scores predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resistant prostate cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5035-5035

2023

Volltextzugriff (PDF)

Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5010-5010

2023

Volltextzugriff (PDF)

Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.534-534

2023

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(173)

Publikationsform

Artikel
(174)
Tagungsberichte
(1)

Sprache

Englisch
(175)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Aged
(5)
Humans
(5)
Male
(5)
Science & Technology
(5)
Life Sciences & Biomedicine
(4)
Middle Aged
(3)
Quality Of Life
(3)
Adaptation
(2)
Aged, 80 And Over
(2)
Biological And Medical Sciences
(2)
Female
(2)
Medical Sciences
(2)
Oncology
(2)
Prostate Cancer
(2)
Psychosocial
(2)
Tumors
(2)
Actins
(1)
Adaptation, Psychological
(1)
Adult And Adolescent Clinical Studies
(1)
Age Factors
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)

Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): A post-hoc analysis of the SPARTAN phase III trial

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

Evaluating changes in “good safety monitoring” for cancer clinical trial participants during the COVID-19 pandemic

Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer

Disparities in germline testing by race/ethnicity and preferred language in patients with prostate cancer

Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies

Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer

Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study

Ethnic disparities among men with prostate cancer undergoing germline testing

HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC)

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Patterns in cancer management changes for patients with COVID-19 in northern California

Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy

Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)

Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC)

The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies

Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center

Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging

Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET

AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)

Digital histopathology-based multimodal artificial intelligence scores predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resistant prostate cancer

Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study

Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB)

Suchergebnisse filtern